Literature DB >> 21592456

Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.

Stephen Deppen1, Joe B Putnam, Gabriela Andrade, Theodore Speroff, Jonathan C Nesbitt, Eric S Lambright, Pierre P Massion, Ron Walker, Eric L Grogan.   

Abstract

BACKGROUND: The 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is used to evaluate suspicious pulmonary lesions due to its diagnostic accuracy. The southeastern United States has a high prevalence of infectious granulomatous lung disease, and the accuracy of FDG-PET may be reduced in this population. We examined the diagnostic accuracy of FDG-PET in patients with known or suspected non-small cell lung cancer treated at our institution.
METHODS: A total of 279 patients, identified through our prospective database, underwent an operation for known or suspected lung cancer. Preoperative FDG-PET in 211 eligible patients was defined by standardized uptake value greater than 2.5 or by description ("moderate" or "intense") as avid. Sensitivity, specificity, positive and negative predictive values, likelihood ratios, and decision diagrams were calculated for FDG-PET in all patients and in patients with indeterminate nodules.
RESULTS: In all eligible patients (n=211), sensitivity and specificity of FDG-PET were 92% and 40%, respectively. Positive and negative predictive values were 86% and 55%. Overall FDG-PET accuracy to diagnose lung cancer was 81%. Preoperative positive likelihood ratio for FDG-PET diagnosis of lung cancer in this population was 1.5 compared with previously published values of 7.1. In 113 indeterminate lesions, 65% had lung cancer and the sensitivity and specificity were 89% and 40%, respectively. Twenty-four benign nodules (60%) had false positive FDG-PET scans. Twenty-two of 43 benign nodules (51%) were granulomas.
CONCLUSIONS: In a region with endemic granulomatous diseases, the specificity of FDG-PET for diagnosis of lung cancer was 40%. Clinical decisions and future clinical predictive models for lung cancer must accommodate regional variation of FDG-PET scan results.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21592456      PMCID: PMC3186439          DOI: 10.1016/j.athoracsur.2011.02.052

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  28 in total

1.  Prevalence of histoplasmosis in a midsouthern population.

Authors:  R J Leggiadro; G S Luedtke; A Convey; L Gibson; F F Barrett
Journal:  South Med J       Date:  1991-11       Impact factor: 0.954

2.  Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule.

Authors:  Catherine Lejeune; Kazem Al Zahouri; Marie-Christine Woronoff-Lemsi; Patrick Arveux; Alain Bernard; Christine Binquet; Francis Guillemin
Journal:  Eur J Health Econ       Date:  2005-09

3.  SUV: standard uptake or silly useless value?

Authors:  J W Keyes
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

4.  Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application.

Authors:  J W Gurney; D M Lyddon; J A McKay
Journal:  Radiology       Date:  1993-02       Impact factor: 11.105

5.  Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan.

Authors:  N A Dewan; C J Shehan; S D Reeb; L S Gobar; W J Scott; K Ryschon
Journal:  Chest       Date:  1997-08       Impact factor: 9.410

Review 6.  Pulmonary histoplasmosis.

Authors:  J W Gurney; D J Conces
Journal:  Radiology       Date:  1996-05       Impact factor: 11.105

7.  Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.

Authors:  Carolyn E Reed; David H Harpole; Katherine E Posther; Sandra L Woolson; Robert J Downey; Bryan F Meyers; Robert T Heelan; Homer A MacApinlac; Sin-Ho Jung; Gerard A Silvestri; Barry A Siegel; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

8.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.

Authors:  Robert James Cerfolio; Buddhiwardhani Ojha; Ayesha S Bryant; Vanguru Raghuveer; James M Mountz; Alfred A Bartolucci
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

9.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

Authors:  S S Gambhir; C K Hoh; M E Phelps; I Madar; J Maddahi
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

Review 10.  Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Authors:  Michael K Gould; Ware G Kuschner; Chara E Rydzak; Courtney C Maclean; Anita N Demas; Hidenobu Shigemitsu; Jo Kay Chan; Douglas K Owens
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

View more
  34 in total

1.  Magnetic resonance imaging of pulmonary nodules: accuracy in a granulomatous disease-endemic region.

Authors:  Natália Henz Concatto; Guilherme Watte; Edson Marchiori; Klaus Irion; José Carlos Felicetti; José Jesus Camargo; Bruno Hochhegger
Journal:  Eur Radiol       Date:  2015-12-05       Impact factor: 5.315

Review 2.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 3.  The Pursuit of Noninvasive Diagnosis of Lung Cancer.

Authors:  Thomas Atwater; Christine M Cook; Pierre P Massion
Journal:  Semin Respir Crit Care Med       Date:  2016-10-12       Impact factor: 3.119

4.  Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.

Authors:  Mohamed Hassanein; Matthew R Hight; Jason R Buck; Mohammed N Tantawy; Michael L Nickels; Megan D Hoeksema; Bradford K Harris; Kelli Boyd; Pierre P Massion; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

5.  Evidence based imaging strategies for solitary pulmonary nodule.

Authors:  Yi-Xiang J Wang; Jing-Shan Gong; Kenji Suzuki; Sameh K Morcos
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 6.  Imaging of solitary pulmonary nodule-a clinical review.

Authors:  Yee Ting Sim; Fat Wui Poon
Journal:  Quant Imaging Med Surg       Date:  2013-12

7.  Image-guided drug delivery in lung cancer.

Authors:  Timothy S Wiedmann; Tanmoy Sadhukha; Bruce E Hammer; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2012-02       Impact factor: 4.617

8.  Assessment of Fluorodeoxyglucose F18-Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules.

Authors:  Amelia W Maiga; Stephen A Deppen; Sarah Fletcher Mercaldo; Jeffrey D Blume; Chandler Montgomery; Laszlo T Vaszar; Christina Williamson; James M Isbell; Otis B Rickman; Rhonda Pinkerman; Eric S Lambright; Jonathan C Nesbitt; Eric L Grogan
Journal:  JAMA Surg       Date:  2018-04-01       Impact factor: 14.766

9.  Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer.

Authors:  Eric L Grogan; Stephen A Deppen; Karla V Ballman; Gabriela M Andrade; Francys C Verdial; Melinda C Aldrich; Chiu L Chen; Paul A Decker; David H Harpole; Robert J Cerfolio; Robert J Keenan; David R Jones; Thomas A D'Amico; Joseph B Shrager; Bryan F Meyers; Joe B Putnam
Journal:  Ann Thorac Surg       Date:  2014-02-25       Impact factor: 4.330

Review 10.  Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancer.

Authors:  Shaheen Islam; Ronald C Walker
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.